MedTrace Logo

Study on Delayed Graft Function Using Paired Kidneys

NCT01561599 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-02-22

No results posted yet for this study

Summary

The study is designed to evaluate the safety and efficacy of an intravenously administered drug in recipients of kidneys from cardiac death donors who are risk for developing delayed graft function.

Conditions

  • Delayed Graft Function

Interventions

DRUG

BB3

Daily intravenous administration of 2mg/kg for 4 days

DRUG

Normal Saline

Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Angion Biomedica Corp

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2016-02-29
Completion
2016-05-31

Countries

  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01561599 on ClinicalTrials.gov